ライフサイエンスコーパス: low molecular weight

1 a fraction was exerted by sub-fractions with low molecular weight.

2 quences extracted from natural structures of low molecular weight.

3 r into a moderate PI3Kalpha inhibitor with a low molecular weight.

4 stems as compared to systems in which model, low-molecular-weight 1O2 sensitizers were used.

5 Attracted by the low molecular weight (270 g.mol(-1)) of our starting hit

6 ough permeable TJ, we intravenously injected low molecular weight (3 kDa) dextran in combination with

7 Experimental results evidenced that low molecular weight (50-190 kDa) chitosan can be used t

8 S100 family genes encode low molecular weight, acidic-Ca(2+) binding proteins imp

9 eaction to a variety of organic materials or low molecular weight agents that are present in the work

10 tem, which showed improved responsivities to low molecular weight alcohols compared to similar sensor

11 ation of the tocopherols and the emission of low-molecular-weight aldehydes better than BHT and with

12 Therefore, low molecular weight alginate produced by heating could

13 The resulting low molecular weight alginates were investigated by UV-v

14 ks in the polymer chain and so generation of low molecular weight alginates.

15 t hydrocarbon oligomers are alternatives for low molecular weight alkane solvents.

16 e of atmospheric organic nitrogen, including low molecular weight alkyl-amines.

17 group of previous FKBP51 ligands by various low molecular weight amides.

18 iazine 2, a potent BACE1 inhibitor, led to a low molecular weight aminothiazine 5 with moderate activ

19 approaches in investigating the mechanism of low-molecular-weight amyloid inhibitors.

20 The sputtered fibers extracted low molecular weight analytes that were not detectable w

21 mpounds would be an ideal tool for screening low-molecular weight analytes (<2000 Da) having many var

22 rations of thrombin (10(-18) m) as well as a low molecular weight anatoxin (165 Da, 10(-14) m) are de

23 ion of small molecules associated with their low molecular weight and electrical charge, we incorpora

24 hly potent and selective ERK inhibitors with low molecular weight and high LE.

25 Distinct gel patterns, due to proteins with low molecular weight and low isoelectric points, disting

26 isomerization in heptane and a PAO show that low molecular weight and oligomeric carboxylic acids are

27 Frankia CcI3 supernatant are hydrophilic, of low molecular weight and resistant to chitinase degradat

28 The development of low molecular weight anionophores is an emerging topic i

29 was determined in vitro as the depletion of low-molecular-weight antioxidants (ascorbate and glutath

30 PF-3450074 (PF74), an HIV-1 capsid-targeting low-molecular-weight antiviral compound, directly binds

31 soft materials are formed by self-assembling low-molecular-weight building blocks, which can be progr

32 isiae for 5h removed coextracted interfering low molecular weight carbohydrates from extracts of diff

33 Several low-molecular-weight carbohydrates exhibit the same effe

34 stead, fragmentation produces polyfunctional low molecular weight carboxylic acids after oxidative cl

35 lexity of a wet adhesive primer to synthetic low-molecular-weight catecholic zwitterionic surfactants

36 ray ionization mass spectrometry (ESI-MS) of low molecular weight cationic samples prepared in SDS co

37 of siRNA can be effectively complexed with a low-molecular-weight, cationic polymer (poly(beta-amino

38 ria, fungi, animal proteins, plant proteins, low molecular weight chemicals, and metals.

39 Low-molecular-weight chemicals that likely derive from b

40 lish this, C. albicans white cells secrete a low-molecular-weight chemoattractive stimulant(s) of mac

41 Low molecular weight chitosan exerted a potent inhibitor

42 an un-supplemented state is associated with low molecular weight circulating metabolites.

43 The addition of low molecular-weight co-pigments such as gallic acid and

44 tal data show that CPEB exists in at least a low-molecular weight coiled-coil oligomeric form and an

45 ed propeptides copurified as a heterodimeric low molecular weight complex that stimulated Activin rec

46 omatographic methods were adapted to isolate low-molecular-weight components.

47 Finally, the low molecular weight compound diclofenac was bound to th

48 SMN-C1 is a low-molecular weight compound that promotes the inclusio

49 nalyses was used to determine changes in the low-molecular-weight compound composition of peanuts due

50 s able to detect low submicrogram amounts of low molecular weight compounds (<500 Da).

51 at unravelling the antioxidative capacity of low molecular weight compounds (LMWC) (peptides, amino a

52 ed drug design exploits initial screening of low molecular weight compounds and their concomitant aff

53 olecular imaging of exogenous and endogenous low molecular weight compounds from fingerprints.

54 when allergens were tested together with the low molecular weight compounds from pollen.

55 se of the unique composition of proteins and low molecular weight compounds present in the circulator

56 Besides allergens, pollen release bioactive, low molecular weight compounds that modulate and stimula

57 By contrast, analysis of low molecular weight compounds with this technique has b

58 ancers, in particular blocking Siglec-7 with low molecular weight compounds.

59 ction of an analyte group comprising similar low-molecular weight compounds exhibiting the benefits o

60 olomics to perform quantitative profiling of low-molecular weight compounds from biological specimens

61 fermentation, with a concurrent increase in low-molecular-weight compounds (hydroxybenzoic and hydro

62 We report the synthesis and evaluation of 3 low-molecular-weight compounds labeled with (86)Y for im

63 ignificant impact on the levels and types of low-molecular-weight compounds present.

64 oduced for measuring the binding kinetics of low-molecular-weight compounds to their biomolecular tar

65 Plants produce diverse low-molecular-weight compounds via specialized metabolis

66 Compared to low-molecular-weight compounds, little information is av

67 ponsible for chain transfer and formation of low molecular weight copolymers in the traditional catal

68 significantly impacts the design of potent, low molecular weight COT kinase inhibitors.

69 h(-1) bar(-1) for acetone, with an unchanged low molecular weight cut off (~250 Da).

70 ication steps including ultrafiltration with low molecular weight cut-off membranes, cation exchange

71 However, the oncogenic forms of cyclin E (low molecular weight cyclin E or LMW-E) in complex with

72 nitrification, is prone to the production of low-molecular-weight dissolved organic N (LMW-DON), whic

73 of the reactivity of HS(-) toward symmetric low molecular weight disulfides (RSSR) and mixed albumin

74 , which are more efficacious in vitro than a low molecular weight drug against SCD1, and critically d

75 BB shuttles have been developed to transport low-molecular-weight drug candidates to the brain which

76 olecular therapeutics that avoids the use of low molecular weight drugs.

77 een developed, which include the coupling of low-molecular weight drugs to exogenous or endogenous al

78 n identified as recognizable biomolecules of low molecular weight (e.g., inositol hexakisphosphates).

79 udomonas aeruginosa quorum-sensing-regulated low-molecular-weight excreted molecule, triggers autolys

80 occurs in conjunction with precipitation of low molecular weight Fe(III) species (e.g., monomers, di

81 0 kDa) was markedly different to that of the low molecular weight fraction (<10 kDa).

82 Aqueous ragweed pollen extract, the low molecular weight fraction or the major allergen Amb

83 xtract, but not of the major allergen or the low molecular weight fraction, induced specific IgG1 , p

84 The low-molecular-weight fraction and phytoprostane E1 (PPE1

85 oidal phases of the sediments but not in the low molecular weight fractions (<1000 Da).

86 ng a synergistic effect between the high and low molecular weight fractions for NP stabilization.

87 vitro study showed that EMD and its high and low molecular weight fractions reduced the secretion of

88 kinetics, but only one of the formulations (low molecular weight, free acid terminated) exhibited th

89 The low molecular weight G protein RhoA (rat sarcoma virus h

90 MRI studies have typically used low molecular weight gadolinium contrast agents, however

91 We have synthesized three new high-affinity, low-molecular-weight Gd(III) -based PSMA-targeted contra

92 tly affect the properties of a solution of a low-molecular-weight gelator at high pH.

93 he hierarchically organized self-assembly of low molecular weight gelators (LMWGs) based on non-coval

94 diacetylene glycolipids that can function as low molecular weight gelators are particularly interesti

95 Hydrogels formed by the self-assembly of low-molecular-weight gelators (LMWGs) are promising scaf

96 multicomponent gel is first formed from two low-molecular-weight gelators and consists of two types

97 in multicomponent gels based on programmable low-molecular-weight gelators, with one network being po

98 (55-20 kDa; gliadins), peak III (28-10 kDa; low molecular weight gliadins), peak IV and V (<10 kDa;

99 er and a 26-mer) found in omega-gliadins and low-molecular-weight glutenins that had been identified

100 e demonstrate here the stabilizing effect of low-molecular-weight glycans on both spherical and rod-l

101 While low molecular weight HA increases sensitivity to mechani

102 to potable quality have difficulty removing low molecular weight halogenated disinfection byproducts

103 The low molecular weight hapten, Ochratoxin A (OTA), is a na

104 The development of antibodies to low molecular weight haptens remains challenging due to

105 The potential of low molecular weight heparin (LMWH) in anti-angiogenic t

106 We hypothesized that low molecular weight heparin (LMWH) is superior to unfra

107 Evidence has suggested that low molecular weight heparin (LMWH) might improve surviv

108 d Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Pla

109 l calf compression devices and perioperative low molecular weight heparin, is approximately 2%.

110 asone should receive prophylaxis with either low-molecular weight heparin (LMWH) or low-dose aspirin.

111 ithrombotic treatment (low-dose aspirin plus low-molecular weight heparin [LDA+LMWH]) for obstetric a

112 eatments included substitution of heparin or low-molecular weight heparin for warfarin (n = 13 [72%])

113 Enoxaparin, a low-molecular weight heparin, is effective in prevention

114 unfractionated heparin or, less commonly, to low-molecular weight heparin.

115 eceive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per k

116 ants were used in 24% (n=665), predominantly low-molecular-weight heparin (73%, n=487) and unfraction

117 ts did not differ from that with warfarin or low-molecular-weight heparin (factor Xa vs warfarin IRR

118 ned to receive either a prophylactic dose of low-molecular-weight heparin (for the 8 days after arthr

119 Low-molecular-weight heparin (in comparison to unfractio

120 We have shown previously that the GAG low-molecular-weight heparin (LMWH) binds to Abeta40 fib

121 ada, since 2006, involved replacing UFH with low-molecular-weight heparin (LMWH) for prophylactic and

122 g events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomize

123 A daily injection of low-molecular-weight heparin (LMWH) is often prescribed

124 etween perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated he

125 partum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clear

126 K antagonist (VKA) throughout pregnancy; 2) low-molecular-weight heparin (LMWH) throughout pregnancy

127 is of randomized controlled trials comparing low-molecular-weight heparin (LMWH) vs no LMWH in women

128 the risk was not different between NOACs and low-molecular-weight heparin (RR, 2.13; 95% CI, 0.22-20.

129 vs dabigatran 0.88 [0.59-1.36]; factor Xa vs low-molecular-weight heparin 1.02 [0.42-2.70]; and low-m

130 ding compared with sequential treatment with low-molecular-weight heparin and a vitamin K antagonist

131 r than conventional anticoagulation therapy (low-molecular-weight heparin followed by vitamin K antag

132 oral anticoagulant compared with warfarin or low-molecular-weight heparin for all indications.

133 tal venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followe

134 s of our trials showed that prophylaxis with low-molecular-weight heparin for the 8 days after knee a

135 s noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arter

136 lation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perio

137 dditional clinical trials of edoxaban versus low-molecular-weight heparin for the treatment of venous

138 thromboembolism, and they are comparable to low-molecular-weight heparin for thromboprophylaxis afte

139 For initial treatment, use of low-molecular-weight heparin increased from 77% to 84%,

140 nd placebo-controlled trial on the effect of low-molecular-weight heparin is lacking.

141 Low-molecular-weight heparin is recommended over warfari

142 Low-molecular-weight heparin is the standard treatment f

143 ceived anticoagulant thromboprophylaxis with low-molecular-weight heparin or unfractionated heparin a

144 Failure of standard thromboprophylaxis using low-molecular-weight heparin or unfractionated heparin i

145 bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control

146 monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-yea

147 use only the combination of anti-DC-SIGN and low-molecular-weight heparin prevented binding.

148 uation of anticoagulants, dose reduction, or low-molecular-weight heparin replacement.

149 Blocking endothelial cell activation by the low-molecular-weight heparin tinzaparin was accompanied

150 lecular-weight heparin 1.02 [0.42-2.70]; and low-molecular-weight heparin vs dabigatran 0.67 [0.20-1.

151 Low-molecular-weight heparin was used in 88% of the preg

152 ibitors, chronic kidney disease, anemia, and low-molecular-weight heparin within 48-hour pre-PCI.

153 itial treatment with unfractionated heparin, low-molecular-weight heparin, or fondaparinux, usually o

154 h the administration of therapeutic doses of low-molecular-weight heparin, we performed a matched, re

155 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

156 ypercoagulable state, which was treated with low-molecular-weight heparin.

157 ral anticoagulants compared with warfarin or low-molecular-weight heparin.

158 th direct oral anticoagulants, warfarin, and low-molecular-weight heparin.

159 in binding of various glycosaminoglycans and low molecular weight heparins by microscale thermophores

160 Low-molecular weight heparins (LMWH) prepared by partial

161 oral vitamin K antagonists and subcutaneous low-molecular-weight heparins (LMWHs).

162 (MN) arrays for the facilitated delivery of low molecular weight, high dose drugs.

163 Low molecular weight hyaluronan (LMWH) acts at both pept

164 s of other biomarkers, especially those with low molecular weight in complex biological samples.

165 erface and by targeting the interface with a low molecular weight inhibitor, we show that TNFalpha re

166 ified the triterpenoid Celastrol as a potent low-molecular-weight inhibitor of the interaction of Myb

167 Radiolabeled urea-based low-molecular weight inhibitors of the prostate-specific

168 indicating ebselen as one of the most potent low-molecular-weight inhibitors of bacterial ureases rep

169 y used as alternate matrices to minimize the low molecular weight interferences observed in typical M

170 The MIP selectivity against low-(molecular weight) interferences, common for physiol

171 Purpose To synthesize two low-molecular-weight iron chelates and compare their T1

172 ore, intact G1/S transition (Rb-positive and low-molecular-weight isoform of cyclin E (cytoplasmic)-n

173 s NK-DeltaLP strain can produce high-purity, low-molecular-weight levan, but production is relatively

174 oteins with other proteins, nucleic acids or low molecular-weight ligands, both in the viral particle

175 elative to other proteins, nucleic acids and low molecular-weight ligands.

176 hibitors were intensively studied to develop low-molecular-weight ligands for imaging prostate cancer

177 ed by the experimental evidence ranging from low molecular weight liquids and polymers to plastic cry

178 protein in the blood as lysozyme and also a Low Molecular Weight (LMW) ACE effector, bilirubin, whic

179 in (Ig)-E in occupational asthma (OA) due to low molecular weight (LMW) agents is not well establishe

180 in distinct high molecular weight (HMW) and low molecular weight (LMW) peaks.

181 n of Maillard reaction (MR), induced between low molecular weight (LMW) peptides and sucrose, was stu

182 Compromise of this pathway results in low molecular weight (LMW) proteinuria that can progress

183 Mycothiol (MSH) is the major low molecular weight (LMW) thiol in Actinomycetes.

184 We used low molecular weight (LMW, 18 kDa) FGF-2 and high molecu

185 Hs that are considerably more toxic than the low molecular weight (LMW, 2-3 ring) PAHs.

186 cyclin E is posttranslationally cleaved into low molecular weight (LMW-E) isoforms, which are tumor-s

187 ented compared to the starting material, and low molecular-weight (LMW) species.

188 ct that was then fractionated for elution of low-molecular weight (LMW) and high-molecular weight (HM

189 The effect of addition of the low-molecular weight (LMW) organic compounds, easily ion

190 Low-molecular weight (LMW) phthalate diesters function a

191 Low-molecular-weight (LMW) and high-molecular-weight (HM

192 oss to microbial uptake was derived from the low-molecular-weight (LMW) organic acids acetate and but

193 activated without apparent dissociation into low-molecular-weight (LMW) species after RNase A treatme

194 Staphylococcus aureus does not produce the low-molecular-weight (LMW) thiol glutathione, but it doe

195 Mercury complexation by low-molecular-weight (LMW) thiols can affect its bioavai

196 We found that constitutive secretion of low-molecular-weight (LMW) VWF is targeted basolaterally

197 : medium molecular weight, 40-<1.3 kDa; LMW: low molecular weight, <1.3 kDa).

198 , various fatty acids as well as on numerous low-molecular-weight metabolites, including amino acids,

199 d with the enantioselective recognition of a low molecular weight model compound, L-tyrosinamide (L-T

200 chemistry toward the discovery and design of low molecular weight molecules that affect stem cells an

201 II as gliadins (20-55kDa), peak III as very low molecular weight monomeric gliadins (10-28kDa), peak

202 e-radical polymerization of water-insoluble, low-molecular-weight monomers that show a large change i

203 his challenge, many aerobic microbes produce low molecular weight (MW) organic ligands, or siderophor

204 This low molecular weight mycotoxin is analyzed using an indi

205 These results establish the advantage of low molecular weight, narrow polydispersity, and amorpho

206 mpetitive immunoassays, for the detection of low molecular weight natural toxicants, as an alternativ

207 of an approach for the reliable discovery of low molecular weight, nonpeptidic fragment substrates of

208 rbon oligomers behave as solvents like their low molecular weight nonpolar hydrocarbon solvents and t

209 cape model, we predict the structures of the low-molecular weight oligomeric form and the dynamics of

210 led to their quantitative dissociation into low molecular weight oligomers ( approximately 8-70 kDa)

211 into low molecular weight species, and these low molecular weight oligomers are significantly more bi

212 Low molecular weight oligomers of amyloid-beta (Abeta) h

213 n states, which result from the formation of low molecular weight oligomers, high molecular weight ol

214 Abeta aggregates, especially the low-molecular weight oligomers, are the primary toxic ag

215 This results in soluble low-molecular-weight oligomers that can act as a therape

216 of the self-assembly of molecules, including low molecular weight ones.

217 Low molecular weight organic acids (LMWOAs) represent th

218 A general overview on low molecular weight organic chemistry is given, and the

219 metabolomics, the unbiased study of multiple low molecular weight organic metabolites, to examine how

220 Arguments for an abiotic origin of low-molecular weight organic compounds in deep-sea hot s

221 This system simulates the monitoring of low-molecular weight organic compounds in natural flowin

222 ts detected on the surface of the petals are low-molecular-weight organic acids, sugars, and flavonoi

223 Low molecular weight P2VP-b-PS-b-P2VP triblock copolymer

224 We report a functionally unique family of low-molecular-weight PBPs that act as transpeptidases ra

225 ses that form peptidoglycan cross-links, and low-molecular-weight PBPs, which are typically hydrolase

226 el and convenient approach to generate ultra-low molecular weight pectin with high efficiency and hig

227 oly(ethylenimine) (PEI (-s-s-)) derived from low molecular weight PEI (1.8 kDa) for efficient gene de

228 dings indicate that precise modifications of low molecular weight PEI improve its bio-responsiveness

229 The biological roles of low molecular weight penicillin-binding proteins (LMW PB

230 w value source to produce highly digestible, low molecular weight peptide powders that could be used

231 ell separated protein band of 21.3 kDa and a low molecular weight peptide.

232 rance of globular proteins and generation of low molecular weight peptides (less than 3kDa).

233 PsaI represents one of three low molecular weight peptides of PSI.

234 Both free amino acids and low molecular weight peptides thus seemed to contribute

235 ophoresis showed that beta-lactoglobulin and low molecular weight peptides were cross-linked by trans

236 ptides were determined by UPLC/ESI-MS and 35 low-molecular weight peptides were identified and subjec

237 However, as opposed to conventional low molecular weight pesticides, the environmental fate

238 LDI matrix materials and a variety of common low molecular weight pharmaceutical molecules indeed lea

239 Low molecular weight phenolic compounds (LMWPC), includi

240 gation revealed differential accumulation of low-molecular-weight phenolics, including (glycosylated)

241 s study aims to investigate the stability of low molecular weight phlorotannin fractions from Fucus v

242 EHP) and mono-benzyl phthalate (MBzP), and 3 low-molecular-weight phthalate (LMWP) metabolites (Sigma

243 OPEs with an aromatic structure, 50-100% of low molecular weight phthalates (log KOW 4-6), and < det

244 anar surface area concentrations of OPEs and low molecular weight phthalates were significantly great

245 temperature and pH) to reduce gallic acid, a low molecular weight pigment (MW 170gmol(-1)) widely fou

246 an efficient method to reduce the potential low molecular weight pigment present in the sugarcane.

247 almon) in the glassy state, in mixtures with low molecular weight plasticizers (e.g. glycerol, glucos

248 extend our previous work on phosphorescent, low molecular weight platinum(II) complex as an oxygen s

249 Low molecular weight polyphenols (LMW-PPs) and anthocyan

250 o explain the strong stabilizing effect of a low molecular weight Pony Lake fulvic acid sample to the

251 cess, cells transiently accumulate zinc in a low-molecular-weight pool, and this accumulation is larg

252 Ibbeta3 mAb fused to a thrombin-activatable, low-molecular-weight pro-uPA (PLT/uPA-T).

253 On one hand, after conjugation with low molecular weight protamine (LMWP), a cell penetratin

254 The low molecular weight protein tyrosine phosphatase (LMW-P

255 ficiently high concentration of a relatively low molecular weight protein, cytochrome-c, for ESI-MS d

256 growth medium demonstrated the presence of a low molecular weight proteinaceous secreted factor that

257 Kunitz-type (KT) protease inhibitors are low molecular weight proteins classically defined as ser

258 ght proteins and correlated only weakly with low molecular weight proteins, suggestive of tubular pro

259 of glucosuria, phosphaturia, aminoaciduria, low molecular weight proteinuria, and albuminuria.

260 l Ocrl-knockout mouse background resulted in low molecular weight proteinuria, phosphaturia, and acid

261 ensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging a

262 t library for PDE10A inhibitors identified a low molecular weight pyrimidine hit with PDE10A Ki of 87

263 Investigations on the reactivity of low-molecular-weight quinones, which are believed to be

264 zed TAG72 targeting diabody, AVP04-07, and a low-molecular-weight radiolabeled tetrazine probe that w

265 gy by overcoming the high renal retention of low-molecular-weight radiometal tumor-homing agents thro

266 8)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a low-molecular-weight radiotracer that targets the prosta

267 t tissues contain reservoirs of microRNAs in low molecular weight RISC (LMW-RISC) not bound to mRNA,

268 A combination of low molecular weight salts and proteins makes the glue v

269 master mix, while restriction digestion of a low molecular weight sample also caused underestimation.

270 e broadly, this work suggests that flexible, low-molecular-weight sequence-defined polymers can serve

271 s and evaluation of the first, high-affinity low molecular weight Siglec-7 ligands to interfere with

272 c organs or phylogenetic groups, termed seed low-molecular-weight (SL; seed plants), seed high-molecu

273 cal pretreatments to extract and concentrate low molecular weight SMPs (MW< 580 Da) from effluents we

274 The stabilized low molecular weight species are nontoxic.

275 technology is generally limited to releasing low molecular weight species that can diffuse through th

276 the abundant HMW oAbeta can dissociate into low molecular weight species, and these low molecular we

277 mers are rationally designed from relatively low-molecular-weight starting materials, with the degree

278 bstrate-based approach to the development of low molecular weight STEP inhibitors with Ki values as l

279 /(mol.e(-)) or less), and must function with low molecular weight supporting electrolytes such as LiB

280 structure, reported for the self-assembly of low molecular weight surfactants, for example, lipids, b

281 The emulsions were stabilized by high- and low-molecular weight surfactants.

282 neral epitope targeting capability for these low molecular weight synthetic ligands enables a range o

283 We describe herein the design of novel, low-molecular-weight, synthetic alpha-helix mimetics tha

284 s have largely focused on the development of low-molecular-weight, synthetic BH3 mimetics ("magic bul

285 M-D) for the enantioselective detection of a low molecular weight target molecule (less than 200 Da)

286 Because of ease of synthesis and low molecular weight, the conjugate base of triethylurea

287 between a protein cysteine and an attacking low molecular-weight thiol have a dramatic effect on the

288 omallei senses host cytosolic glutathione, a low-molecular-weight thiol, through the membrane-bound h

289 k, we examined the reactions of NO2-CLA with low molecular weight thiols (glutathione, cysteine, homo

290 lated and S-cysteinylated peptides, in which low molecular weight thiols are attached to cysteine res

291 osylation of cysteine thiols in proteins and low molecular weight thiols such as GSH.

292 Finally, we demonstrate that some low molecular weight thiols, but importantly not physiol

293 trisulfide can transfer allyl side chains to low molecular weight thiols.

294 Whereas glutathione and other low-molecular-weight thiols have important roles in redo

295 lar bioavailability to Hg(II) complexes with low-molecular-weight thiols.

296 iversity in lignin but still of sufficiently low molecular weight to enable facile analysis.

297 a functionally abnormal vasculature, with a low-molecular-weight tracer accumulating only in periphe

298 of cpSRP is required for the formation of a low molecular weight transit complex with LHCP.

299 in vivo has resulted in more sophisticated, low molecular weight vectors that allow systematic optim

300 mers (-9+/-1%, P<0.0001) and accumulation of low-molecular-weight vWF multimers (+40+/-5%, P<0.0001)